Full-Time
Head of Product Design
Development and Rollout
Posted on 10/31/2025
GenBio AI
51-200 employees
AI-powered biological simulation for drug development
Compensation Overview
$200k - $300k/yr
Palo Alto, CA, USA
In Person
 UI/UX & Design (1) |
|---|
- Bachelor’s, Master’s degree in Computer Science, Engineering, Molecular Biology, or related field. Experience in life sciences or healthcare required
- Deep knowledge of the AI / ML engineering and application field with specific focus on foundational models and deep neural networks.
- Experience with ML / AI products for the consumer (non-expert) markets
- Good understanding of molecular biology and the various types of high throughput data that are being profiled by academia and industry across the life sciences
- Knowledge of engineering and cloud issues relate to the development and deployment of scalable AI solutions is a plus
- Ability to lead an integrate team of data scientists, engineers, UI / UX designers and to ensure coordinated work to the desired outcome
- Hands-on experience developing outward-facing software products, particularly those used directly by clients in the pharma or biotech industries
- Lead all work related to the design, development and rollout for state of the art AI product for the life sciences community
- Work closely with the engineering and application teams to define the needs, determine capabilities and design a roadmap for product release
- Work closely with UI / UX to ensure product features align with user needs and to improve on an ongoing basis to offering
- Interact with the life science community on an ongoing basis to determine product adoption, enhancements and future releases
- Inspiring individual who that can overcome technical and personal challenges to succeed in the planned release strategy
- Passionate about the use of AI / ML in the life sciences
- Combines deep understanding of technical issues with great grasp of what it means to lead a team of highly skilled individuals to a shared goal
GenBio AI develops a digital organism called AIDO to simulate biological processes for drug development and personalized medicine. AIDO uses multiscale models to predict how molecules and cells behave, allowing researchers to test millions of potential treatments digitally to find the most effective options. Unlike traditional methods that rely heavily on physical trials, this platform provides actionable insights across multiple biological levels to improve vaccine safety and clinical diagnostics. The company's goal is to accelerate the creation of new medicines and minimize adverse reactions through partnerships with healthcare providers and research institutions.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Palo Alto, California
Founded
2024
Simplify's Take
What believers are saying
- Phase 1 AIDO released six foundation models covering 796 species for rapid simulations.
- Employee count reached 21-50 with $3.7M revenue and $11.8M valuation since 2024.
- Global offices in California, Paris, and Abu Dhabi expand partnership opportunities.
What critics are saying
- Insilico's 18 AI drugs in trials, including Phase 3 INS018_055, outpace AIDO in 6-12 months.
- Recursion's 25 petabytes data and 200+ programs crush GenBio's unvalidated models in 12-18 months.
- FDA January 2026 guidance mandates Phase 2 validation, halting AIDO adoption in 9-15 months.
What makes GenBio AI unique
- AIDO simulates millions of treatments using multiscale foundation models from DNA to cells.
- Dr. Ziv Bar-Joseph leads multiscale model integration for drug discovery since February 2025.
- Dr. Emma Lundberg drives data strategy as Co-Founder since June 2025.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Unlimited Paid Time Off
Hybrid Work Options
Wellness Program
Mental Health Support
Professional Development Budget
Conference Attendance Budget
Stock Options
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -7%PALO ALTO, Calif., June 17, 2025 /PRNewswire/ -- GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.In this role, Lundberg will focus on the development of GenBio AI's data strategy and other scientific initiatives, advancing its mission to build a generative digital organism
PALO ALTO, Calif., June 17, 2025 /PRNewswire/ - GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.
In this talk, Dominik Klein presents "Mapping cells through time and space with moscot" at the Foundation Models for Biology Seminar Series by GenBio AI.
PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited to announce that Dr. Ziv Bar-Joseph has joined as Co-founder and Chief Scientific Officer.In this role, Bar-Joseph will lead work focused on the integration and use of GenBio AI's multiscale foundation models, ensuring they drive real impact in drug discovery, medicine, and beyond. His leadership will be pivotal in helping the company transform AI applications in biology and push the boundaries of biological research.Bar-Joseph brings extensive expertise from Sanofi, a leading global pharmaceutical company. As the VP and Head of R&D Data and Computational Sciences, he led multidisciplinary teams in machine learning, computational biology, and data science to accelerate drug and vaccine discovery. He is also the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling, and AI applications in genomics and systems biology